A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521511-40-00

Acronym

CA240-0029

Enrollment

191

Registered

2025-10-24

Start date

2025-11-18

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic non-small cell lung cancer

Brief summary

Phase 2: Progression free survival (PFS) by RECIST v1.1, Phase 3: Progression free survival (PFS) by RECIST v1.1, Phase 3: overall survival (OS).

Detailed description

Phase 2: objective response (OR), disease control (DC), time to objective response (TTOR), and duration of response (DOR)by RECIST v1.1, Phase 3: objective response (OR), disease control (DC), time to objective response (TTOR), duration of response (DOR), progression free survival (PFS) and PFS2 by RECIST v1.1, Phase 2: Treatment-related and all-cause adverse events (AEs), serious AEs (including fatal AEs); AEs leading to dose interruption, dose reduction, and study treatment discontinuation and laboratory abnormalities

Interventions

DRUGMRTX1719

DRUGCARBOPLATIN

DRUGCISPLATIN

DRUGPEMETREXED

DRUGMRTX1719 Matching Placebo

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGPEMBROLIZUMAB

DRUGPACLITAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase 2: Progression free survival (PFS) by RECIST v1.1, Phase 3: Progression free survival (PFS) by RECIST v1.1, Phase 3: overall survival (OS).	—

Secondary

Measure	Time frame
Phase 2: objective response (OR), disease control (DC), time to objective response (TTOR), and duration of response (DOR)by RECIST v1.1, Phase 3: objective response (OR), disease control (DC), time to objective response (TTOR), duration of response (DOR), progression free survival (PFS) and PFS2 by RECIST v1.1, Phase 2: Treatment-related and all-cause adverse events (AEs), serious AEs (including fatal AEs); AEs leading to dose interruption, dose reduction, and study treatment discontinuation and laboratory abnormalities	—

Measure

Time frame

—

Countries

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026